港股異動 | 和黃醫藥急升逾 5% 沃瑞沙於中國首次商業銷售 獲阿斯利康里程碑付款

智通財經
2021.07.15 05:54
智通財經 APP 獲悉，和黃醫藥 (00013) 發佈公告，沃瑞沙 (通用名：賽沃替尼/savolitinib) 於今年 7 月 12 日首次在中國進行商業銷售，觸發阿斯利康 (AZN.US) 一筆 2500 萬美元的里程碑付款。截至發稿，和黃醫藥漲 4.87%，報 60.25 港元，成交額 3699.57 萬港元。
Source: 智通財經 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.